(Q35211260)

7 August 2017

1 reference

title

Variables in predicting survival based on treating "PSA-only" relapse (English)

1 reference

7 August 2017

Judd W Moul

1

1 reference

7 August 2017

publication date

1 July 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

21

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

292-304

1 reference

7 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Treatment options after failure of local curative treatments in prostate cancer: a controversial issue

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Prostate biopsy quantitative histology as a staging and prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

A catalog of prostate cancer nomograms

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Management of prostate cancer after prostatectomy: treating the patient, not the PSA

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Indium-111 Capromab Pendetide (ProstaScint) Images Before and After Salvage Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Effect of Adjuvant Radiation Therapy on Prostate Specific Antigen Following Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Serum prostate-specific antigen after post-prostatectomy radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

The role of radical surgery in the management of radiation recurrent and large volume prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Salvage brachytherapy for localized prostate cancer after radiotherapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Estrogens in the Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Combined androgen blockade in prostate cancer: meta-analyses and associated issues

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900103-0

7 January 2021

10.1016/S1078-1439(03)00103-0

Identifiers

DOI

1 reference

7 August 2017

1 reference